Edition:
India

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.70EUR
19 Jan 2018
Change (% chg)

€-0.88 (-34.06%)
Prev Close
€2.58
Open
€1.57
Day's High
€1.79
Day's Low
€1.45
Volume
19,932,602
Avg. Vol
1,138,411
52-wk High
€4.26
52-wk Low
€1.45

Chart for

About

Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical... (more)

Overall

Beta: 1.53
Market Cap(Mil.): €690.21
Shares Outstanding(Mil.): 222.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint

* CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT Source text for Eikon:

18 Jan 2018

BRIEF-Pharma Mar Requests Re-Examination Process For Aplidin From EMA

* REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA)

03 Jan 2018

BRIEF-Pharma Mar Signs Distribution License Agreement For Aplidin In Israel

* SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

02 Jan 2018

BRIEF-Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment

* THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA

15 Dec 2017

BRIEF-Pharma Mar Presents Positive Phase III Trial Results Of Plitidepsin In Multiple Myeloma

* SAYS PRESENTS POSITIVE RESULTS OF ADMYRE PHASE III TRIAL OF PLITIDEPSIN IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Dec 2017

BRIEF-Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue

* PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE) Source text for Eikon:

15 Nov 2017

BRIEF-Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma

* PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA

13 Nov 2017

BRIEF-Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment

* SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY

09 Nov 2017

BRIEF-Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre

* SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA

07 Nov 2017

BRIEF-Pharma Mar 9-month net loss narrows to 14.5 mln euros YoY

* 9-MONTH REVENUE 140.4 MILLION EUROS VERSUS 139.6 MILLION EUROS YEAR AGO

24 Oct 2017

Earnings vs. Estimates